This company has been marked as potentially delisted and may not be actively trading. aTyr Pharma (LIFE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5?March 27, 2025 | insidermonkey.comaTyr Pharma (ATYR) Receives a Buy from Wells FargoMarch 18, 2025 | markets.businessinsider.comaTyr Pharma director buys $15K in common stockMarch 18, 2025 | markets.businessinsider.comaTyr Pharma’s Earnings Call Highlights Progress and ChallengesMarch 14, 2025 | tipranks.comaTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...March 14, 2025 | gurufocus.comQ4 2024 aTyr Pharma Inc Earnings Call TranscriptMarch 14, 2025 | gurufocus.comaTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Estimates, Revenue at $0. ...March 13, 2025 | gurufocus.comAtyr Pharma Shares Rise After Lung Disease Treatment Passes Safety ReviewMarch 7, 2025 | marketwatch.comaTyr Pharma, Inc.: aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT Study in Pulmonary SarcoidosisMarch 7, 2025 | finanznachrichten.deaTyr Pharma announces DSMB recommendation for EFZO-FIT study to continueMarch 7, 2025 | markets.businessinsider.comTREATMENT.COM AI INC. ANNOUNCES LISTED ISSUER FINANCING EXEMPTION (LIFE) BOUGHT DEAL PRIVATE PLACEMENTFebruary 27, 2025 | globenewswire.comAmerican Tungsten Announces Closing of Upsized and Oversubscribed Non-Brokered LIFE Offering of SharesFebruary 26, 2025 | globenewswire.comLeerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFebruary 19, 2025 | msn.comaTyr Pharma initiated with an Outperform at LeerinkFebruary 18, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: aTyr Pharma (ATYR), Crispr Therapeutics AG (CRSP) and American Well (AMWL)February 13, 2025 | markets.businessinsider.comSeveral Insiders Invested In aTyr Pharma Flagging Positive NewsJanuary 10, 2025 | finance.yahoo.comaTyr Pharma: Interesting Drug, Difficult Target MarketJanuary 8, 2025 | seekingalpha.comaTyr Pharma initiated with an Overweight at Cantor FitzgeraldJanuary 7, 2025 | markets.businessinsider.comCantor Fitzgerald Initiates Coverage of aTyr Pharma (ATYR) with Overweight RecommendationJanuary 7, 2025 | msn.comaTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comaTyr Pharma to present preclinical research on ATYR0101 at symposia on FirbosisDecember 10, 2024 | markets.businessinsider.comaTyr Pharma stock rated Buy; Lucid notes Efzofitimod's potential in lung diseasesNovember 21, 2024 | uk.investing.comaTyr Pharma initiated with a Buy at Lucid CapitalNovember 20, 2024 | markets.businessinsider.comCerro de Pasco Resources Announces Amendment to LIFE Offering DocumentNovember 19, 2024 | globenewswire.comIs aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comVERSES Closes Second Tranche of LIFE Offering Bringing Aggregate Funds Raised to $5.2M From Recent OfferingsNovember 15, 2024 | globenewswire.comLogos Global Management LP Adjusts Stake in aTyr Pharma IncNovember 15, 2024 | gurufocus.comRBC Capital Sticks to Its Buy Rating for aTyr Pharma (ATYR)November 9, 2024 | markets.businessinsider.comaTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate UpdateNovember 8, 2024 | markets.businessinsider.comPromising Outlook for aTyr Pharma’s Efzofitimod in Pulmonary Sarcoidosis: Buy Rating AffirmedOctober 30, 2024 | markets.businessinsider.comaTyr Pharma: The Bull Has Finally Come OutOctober 24, 2024 | seekingalpha.comaTyr Pharma IncOctober 22, 2024 | morningstar.comWall Street SWOT: aTyr Pharma stock rides wave of clinical progress amid risksSeptember 29, 2024 | investing.comAdare Pharma’s $16.8M Move: Philadelphia’s New Epicenter for Life Sciences and Job SurgeSeptember 24, 2024 | msn.comZydus Lifesciences To Acquire Sterling Biotech's Active Pharmaceutical Ingredients BusinessSeptember 17, 2024 | msn.comaTyr Pharma: Two 2025 Data Readouts Could Provide Inflection PointSeptember 9, 2024 | seekingalpha.comaTyr Pharma Inc.September 6, 2024 | wsj.comJefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy RecommendationSeptember 6, 2024 | msn.comBuy Rating on aTyr Pharma Anchored by Upcoming Clinical Trials and Strong FinancialsAugust 15, 2024 | markets.businessinsider.comaTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical OperationsAugust 6, 2024 | finance.yahoo.comPinnacle Life Science, a Subsidiary of Aarti Drugs Ltd, Enters the US Market with FDA ApprovalAugust 5, 2024 | msn.comaTyr Pharma Announces Research Study with Stanford MedicineJuly 30, 2024 | finance.yahoo.comIndependent Director of aTyr Pharma Paul Schimmel Buys 10.0% More SharesJuly 26, 2024 | finance.yahoo.comBuy Rating Affirmed: aTyr Pharma’s Positive Clinical Developments and Strategic ExpansionJuly 22, 2024 | markets.businessinsider.comaTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary SarcoidosisJuly 22, 2024 | finance.yahoo.comaTyr Pharma (NASDAQ:LIFE) Stock Crosses Above 200-Day Moving Average of $1.65aTyr Pharma (NASDAQ:LIFE) Stock Price Passes Above 200 Day Moving Average of $1.65June 11, 2024 | marketbeat.comMillionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025June 5, 2024 | investorplace.comSanjay Shukla Purchases 20,000 Shares of aTyr Pharma, Inc. (NASDAQ:LIFE) StockJune 4, 2024 | insidertrades.comInsider Buying: aTyr Pharma, Inc. (NASDAQ:LIFE) Director Purchases 50,000 Shares of StockaTyr Pharma, Inc. (NASDAQ:LIFE - Get Free Report) Director Timothy Coughlin acquired 50,000 shares of the firm's stock in a transaction that occurred on Thursday, May 30th. The stock was purchased at an average price of $1.75 per share, with a total value of $87,500.00. Following the completion of the acquisition, the director now owns 56,000 shares in the company, valued at $98,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.June 3, 2024 | marketbeat.comaTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”June 3, 2024 | globenewswire.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address LIFE Media Mentions By Week LIFE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LIFE News Sentiment▼0.000.71▲Average Medical News Sentiment LIFE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LIFE Articles This Week▼01▲LIFE Articles Average Week Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pacific Biosciences of California News Today Harvard Bioscience News Today Thermo Fisher Scientific News Today Agilent Technologies News Today Mettler-Toledo International News Today Waters News Today Illumina News Today Bio-Techne News Today Bio-Rad Laboratories News Today Bruker News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LIFE) was last updated on 4/22/2025 by MarketBeat.com Staff From Our PartnersElon’s 2025 Silver Crisis (What It Means for You)Silver isn't just a safe haven for your wealth—it's a critical resource in the global tech and energy race. Wi...GoldenCrest Metals | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Introducing your AI trading partner. You don't need to stare at charts, stress over setups, or lose sleep. ...Blue Edge Financial | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LIFE Stock Free LIFE Stock Alerts